Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature.


Journal

Acta clinica Belgica
ISSN: 2295-3337
Titre abrégé: Acta Clin Belg
Pays: England
ID NLM: 0370306

Informations de publication

Date de publication:
Feb 2023
Historique:
pubmed: 1 2 2022
medline: 18 1 2023
entrez: 31 1 2022
Statut: ppublish

Résumé

Systemic mastocytosis (SM) is a rare myeloproliferative disease that results from a clonal proliferation of abnormal mast cells in one or more extra-cutaneous organs. Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) is the second most common subgroup and is diagnosed when WHO criteria for both SM and a hematological neoplasm of non-mast cell lineage are met. The SM-AHN category as currently proposed is highly heterogeneous in terms of pathogenesis, clinical presentation, and prognosis. We present the first reported case of SM-AHN associated with two hematological malignancies of different lineages, a monocytic myeloid sarcoma and a B-cell chronic lymphatic leukemia. Cytogenetic and molecular analyses revealed a distinct clonal origin of the two associated malignancies. The SM-myeloid sarcoma clone demonstrated an abnormal karyotype, trisomy 8 and del(13)(q12.3q14.3), as well as mutations in This report highlights the importance of full diagnostic work-up in SM patients in whom an associated hematological malignancy is suspected. Moreover, the importance of genetic analysis is highlighted, as it provides additional insights in the underlying clonal pathogenesis of different phenotypes, can aid in risk stratification, and may help identify potential therapy targets.

Sections du résumé

BACKGROUND UNASSIGNED
Systemic mastocytosis (SM) is a rare myeloproliferative disease that results from a clonal proliferation of abnormal mast cells in one or more extra-cutaneous organs. Systemic mastocytosis with an associated hematological neoplasm (SM-AHN) is the second most common subgroup and is diagnosed when WHO criteria for both SM and a hematological neoplasm of non-mast cell lineage are met. The SM-AHN category as currently proposed is highly heterogeneous in terms of pathogenesis, clinical presentation, and prognosis.
CASE PRESENTATION UNASSIGNED
We present the first reported case of SM-AHN associated with two hematological malignancies of different lineages, a monocytic myeloid sarcoma and a B-cell chronic lymphatic leukemia. Cytogenetic and molecular analyses revealed a distinct clonal origin of the two associated malignancies. The SM-myeloid sarcoma clone demonstrated an abnormal karyotype, trisomy 8 and del(13)(q12.3q14.3), as well as mutations in
CONCLUSIONS UNASSIGNED
This report highlights the importance of full diagnostic work-up in SM patients in whom an associated hematological malignancy is suspected. Moreover, the importance of genetic analysis is highlighted, as it provides additional insights in the underlying clonal pathogenesis of different phenotypes, can aid in risk stratification, and may help identify potential therapy targets.

Identifiants

pubmed: 35098906
doi: 10.1080/17843286.2022.2033919
doi:

Types de publication

Review Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

58-66

Auteurs

Philippe Decruyenaere (P)

Department of Hematology, Ghent University Hospital, Ghent, Belgium.
OncoRNALab, Cancer Research Institute Ghent (Crig), Ghent University, Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.

Dominiek Mazure (D)

Department of Hematology, Ghent University Hospital, Ghent, Belgium.

Ine Moors (I)

Department of Hematology, Ghent University Hospital, Ghent, Belgium.

Jo Van Dorpe (J)

Department of Pathology, Ghent University Hospital, Ghent, Belgium.

Malaïka Van der Linden (M)

Department of Pathology, Ghent University Hospital, Ghent, Belgium.

Barbara Denys (B)

Department of Diagnostic Sciences, Ghent University Hospital, Ghent, Belgium.

Mattias Hofmans (M)

Department of Diagnostic Sciences, Ghent University Hospital, Ghent, Belgium.

Fritz Offner (F)

Department of Hematology, Ghent University Hospital, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH